Molecular Imaging Improves Staging and Treatment of Pancreatic Ductal Adenocarcinomas (Medicine)

For patients with pancreatic ductal adenocarcinomas (PDAC), molecular imaging can improve staging and clinical management of the disease, according to research published in the June issue of The Journal of Nuclear Medicine. In a retrospective study of PDAC patients, the addition of PET/CT imaging with 68Ga-FAPI led to restaging of disease in more than half of the patients, most notably in those with local recurrence.

PDAC is a highly lethal cancer, with a five-year survival rate of less than 10 percent. Optimal imaging of PDAC is crucial for accurate initial TNM (tumor, node, metastases) staging and selection of the primary treatment. Follow-up imaging is also important to accurately detect local recurrence or metastatic spread as early and as completely as possible.

“Currently, contrast-enhanced CT is the gold standard when it comes to TNM staging, and PET imaging isn’t typically part of the clinical routine” stated Manuel Röhrich, MD, nuclear medicine physician at Heidelberg University Hospital in Heidelberg, Germany. “However, we know that PDAC is composed of certain fibroblasts that express fibroblast activation protein, which can be imaged with the novel PET radiotracer 68Ga-FAPI. Given this characteristic, we sought to explore the utility of 68Ga-FAPI PET/CT to image FDAC patients.”

The study included 19 FDAC patients who received contrast-enhanced CT imaging followed by 68Ga-FAPI PET/CT. Results from the 68Ga-FAPI PET/CT scans were then compared with TNM staging based on contrast-enhanced CT. Changes in oncological management were recorded.

68Ga-FAPI PET/CT-based TNM staging differed from contrast-enhanced CT imaging in 10 out of 19 patients, which resulted in changes in TNM staging. Of the 12 patients with recurrent disease, eight were upstaged, one was downstaged and three remained the same. In the seven patients newly diagnosed with PDAC, one was upstaged, while the staging remained the same for six of the patients.

“This analysis suggests that 68Ga-FAPI PET/CT is a promising new imaging modality in staging of PDAC that may help to detect new or clarify inconclusive results obtained by standard CT imaging,” said Röhrich. He added, “Improvement in survival can only be achieved by effective treatment approaches customized to the individual patient’s disease status. Thus, hybrid imaging using FAPI tracer may open up new applications in staging and restaging of PDAC.”

The authors of “Impact of 68Ga-FAPI-PET/CT imaging on the therapeutic management of primary and recurrent pancreatic ductal adenocarcinomas” include Manuel Röhrich, Fabian Staudinger, Dawn, P. Liew, Clemens Kratochwil and Hendrik Rathke, Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany; Patrick Naumann, Jakob Liermann,  Klaus Herfarth and Stefan A. Koerber, Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany, National Center for Tumor diseases (NCT), Heidelberg, Germany, and Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany; Frederik L. Giesel, Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany, and German Cancer Consortium (DKTK), partner site Heidelberg, Germany; Peter L. Choyke, Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Annika Wefers, Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany, and Clinical Cooperation Unit Neuropathology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany; Dirk Jäger, Department of Medical Oncology and Internal Medicine Virgin Islands, National Center for Tumor Diseases, University Hospital Heidelberg, Germany, and Clinical Cooperation Unit Applied Tumor Immunity, German Cancer Research Center (DKFZ), Heidelberg, Germany; Jürgen Debus, Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany, National Center for Tumor diseases (NCT), Heidelberg, Germany, and Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany, German Cancer Consortium (DKTK), Partner Site Heidelberg, Germany, Heidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany, and Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Uwe Haberkorn, Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany, and German Cancer Consortium (DKTK), Partner Site Heidelberg, Germany, Clinical Cooperation Unit, Department of Nuclear Medicine, German Cancer Research Center (DKFZ), Heidelberg, Germany, and Translational Lung Research Center Heidelberg, Member of the German Center for Lung Research DZL, Heidelberg, Germany; and Matthias Lang, Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany, and Department of Surgery, Heidelberg University Hospital, Heidelberg, Germany, Member of the German Center for Lung Research DZL, Heidelberg, Germany.

Featured image: Primary staging of a patient with PDAC. (A) Axial images of PDAC and liver in arterial (upper image) and venous (lower image) ceCT scan. (B) Mean intensity projection (MIP) images of 18F-FDG and FAPI PET/CT imaging. (C) Axial 18F-FDG and FAPI PET/CT images of same patient on level (blue line in A) of pancreatic tumor mass and another suspicious FAPI accumulation in projection on perihepatic lymph node. Metastatic situation, which had been revealed by FAPI PET/CT, was confirmed by biopsy of pulmonary lesion that was diagnosed as metastasis of known PDAC.


Provided by SNMMI

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s